Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Neurosciences Res LLC

Neither a doctor nor a teaching hospital

Research payments

$503,022

49 payments

Through program year 2025, Advanced Neurosciences Res LLC is reported as receiving $503,022 in research payments, across 49 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$61,265	4
2024	Research	$97,020	8
2023	Research	$38,601	10
2022	Research	$46,438	9
2021	Research	$77,766	5
2020	Research	$75,016	5
2019	Research	$106,915	8

Breakdown

Who paid Research payments · program years 2019–2025

Genzyme Corporation $503,022 49 payments

Studies the money was for Research payments · program years 2019–2025

A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) $182,034 6 payments
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $95,686 16 payments
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $59,140 11 payments
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis $48,714 4 payments
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis $46,501 2 payments
A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) $18,147 1 payment
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $12,800 1 payment
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $11,500 1 payment
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) $11,400 1 payment
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $11,400 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.